Deficiency of Adenosine Deaminase 2 in Adults and Children: Experience From India.
Adenosine Deaminase
/ genetics
Adolescent
Adult
Agammaglobulinemia
/ diagnosis
Age of Onset
Anemia
/ physiopathology
Child
Child, Preschool
Delayed Diagnosis
Female
Gastrointestinal Diseases
/ physiopathology
Glucocorticoids
/ therapeutic use
Hematologic Diseases
/ physiopathology
Hemorrhage
/ physiopathology
Humans
India
Infant
Infarction
/ physiopathology
Intercellular Signaling Peptides and Proteins
/ genetics
Kidney Diseases
/ physiopathology
Leukopenia
/ physiopathology
Lung Diseases
/ physiopathology
Male
Myocarditis
/ physiopathology
Nervous System Diseases
/ physiopathology
Pancreatic Diseases
/ physiopathology
Retrospective Studies
Severe Combined Immunodeficiency
/ diagnosis
Stroke
/ physiopathology
Treatment Outcome
Tumor Necrosis Factor Inhibitors
/ therapeutic use
Vasculitis
/ physiopathology
Young Adult
Journal
Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
31
05
2020
revised:
17
07
2020
accepted:
20
08
2020
pubmed:
7
9
2020
medline:
2
3
2021
entrez:
6
9
2020
Statut:
ppublish
Résumé
Deficiency of adenosine deaminase 2 (DADA2) is a potentially fatal monogenic syndrome characterized by variable manifestations of systemic vasculitis, bone marrow failure, and immunodeficiency. Most cases are diagnosed by pediatric care providers, given the typical early age of disease onset. This study was undertaken to describe the clinical phenotypes and treatment response both in adults and in children with DADA2 in India. A retrospective analysis of pediatric and adult patients with DADA2 diagnosed at various rheumatology centers across India was conducted. Clinical characteristics, diagnostic findings, and treatment responses were analyzed in all subjects. In total, 33 cases of DADA2 were confirmed in this cohort between April 2017 and March 2020. Unlike previous studies, nearly one-half of the confirmed cases presented during adulthood. All symptomatic patients exhibited features of vasculitis, whereas constitutional symptoms and anemia were more common in pediatric patients. Cutaneous and neurologic involvement were common, and 18 subjects had experienced at least one stroke. In addition, the clinical spectrum of DADA2 was expanded by recognition of novel features in these patients, including pancreatic infarction, focal myocarditis, and diffuse alveolar hemorrhage. Treatment with tumor necrosis factor inhibitors (TNFi) was initiated in 25 patients. All of the identified disease manifestations showed marked improvement after initiation of TNFi, and disease remission was achieved in 19 patients. Two cases were complicated by tuberculosis infection, and 2 deaths were reported. This report presents the first case series of patients with DADA2 from India, diagnosed by adult and pediatric care providers. The findings raise awareness of this syndrome, particularly with regard to its presentation in adults.
Identifiants
pubmed: 32892503
doi: 10.1002/art.41500
pmc: PMC7902299
mid: NIHMS1630817
doi:
Substances chimiques
Glucocorticoids
0
Intercellular Signaling Peptides and Proteins
0
Tumor Necrosis Factor Inhibitors
0
ADA2 protein, human
EC 3.5.4.4
Adenosine Deaminase
EC 3.5.4.4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
276-285Subventions
Organisme : NIAMS NIH HHS
ID : K08 AR074562
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 AR041083
Pays : United States
Informations de copyright
© 2020, American College of Rheumatology.
Références
J Clin Immunol. 2018 Jul;38(5):569-578
pubmed: 29951947
Arthritis Rheumatol. 2019 Oct;71(10):1747-1755
pubmed: 31008556
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Leukoc Biol. 2010 Aug;88(2):279-90
pubmed: 20453107
Arthritis Rheumatol. 2016 Sep;68(9):2314-22
pubmed: 27059682
Arthritis Rheum. 2010 Feb;62(2):616-26
pubmed: 20112401
JAMA Dermatol. 2015 Nov;151(11):1230-4
pubmed: 26131734
N Engl J Med. 2014 Mar 6;370(10):911-20
pubmed: 24552284
Ann Indian Acad Neurol. 2016 Jan-Mar;19(1):108-11
pubmed: 27011640
J Allergy Clin Immunol. 2018 Apr;141(4):1534-1537.e8
pubmed: 29391253
Neurology. 2004 Mar 23;62(6):878-82
pubmed: 15037685
J Rheumatol. 2015 Aug;42(8):1532-4
pubmed: 26233953
Genomics. 2000 Mar 15;64(3):277-85
pubmed: 10756095
N Engl J Med. 2014 Mar 6;370(10):921-31
pubmed: 24552285
J Clin Immunol. 2018 Apr;38(3):273-277
pubmed: 29564582
Blood. 2017 Dec 14;130(24):2682-2688
pubmed: 28974505
Arthritis Rheumatol. 2017 Aug;69(8):1689-1700
pubmed: 28493328
Muscle Nerve. 2013 Jun;47(6):931-7
pubmed: 23666804
JIMD Rep. 2015;19:85-93
pubmed: 25595217
N Engl J Med. 2019 Apr 18;380(16):1582-1584
pubmed: 30995379
Front Immunol. 2018 Jun 14;9:1361
pubmed: 29963054
Eur J Hum Genet. 2018 Jul;26(7):960-971
pubmed: 29681619
J Pediatr. 2016 Oct;177:316-320
pubmed: 27514238
J Allergy Clin Immunol. 2018 Oct;142(4):1363-1365.e8
pubmed: 29936104
Clin Immunol. 2020 Jun;215:108411
pubmed: 32276138
Cell Mol Life Sci. 2017 Feb;74(3):555-570
pubmed: 27663683
J Rheumatol. 2020 Jan;47(1):117-125
pubmed: 31043544
Biochem J. 2005 Oct 1;391(Pt 1):51-7
pubmed: 15926889
Ann Rheum Dis. 2017 Oct;76(10):1648-1656
pubmed: 28522451
Rheumatology (Oxford). 2019 Jan 1;58(1):181-182
pubmed: 30165497
Rheumatol Int. 2018 Jan;38(1):129-136
pubmed: 28516235
J Allergy Clin Immunol. 2020 Jun;145(6):1664-1672.e10
pubmed: 31945408